Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril·HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration

Publisher Website
Google Scholar
Abstract
The pharmacokinetics of the new angiotensin converting enzyme (ACE) inhibitor benazepril·Ȟl were evaluated in healthy male volunteers. The single dose kinetics were established from data of 62 subjects receiving an oral 10mg dose of the drug. The steady state kinetics were investigated in 15 subjects after once-daily oral doses of 5, 10 or 20 mg. The compound is a prodrug which, on absorption, is hydrolysed to the pharmacologically active metabolite benazeprilat. Thus, plasma concentrations and urinary excretion of parent compound and active metabolite were determined. Benazepril·Ȟl was rapidly absorbed (tmax □ 0·5 h) and rapidly eliminated from plasma (t1/2 □ 0·6 h). Only trace amounts were excreted unchanged in urine. The drug was rapidly metabolized to benazeprilat (tmax □ 1·5 h). The elimination of the metabolite from plasma was biphasic. About 80 per cent of benazeprilat formed was eliminated within 24 h (t1/2 □ 2·7 h), whereas the terminal phase (t1/2 = 22·3 h) controlled a minor amount of elimination. About 17 per cent of dose was excreted in the 24-h urine as benazeprilat. The drug disposition did not change during repeated oral dosing and only small accumulation of the metabolite occurred. The accumulation ratio was 1·20 for AUC and 1·24 for urinary excretion. The effective half-life for accumulation was estimated at about 10–11 h. The comparison with other ACE inhibitors showed similarities but also marked differences with respect to the drug kinetics and excretion.

This publication has 11 references indexed in Scilit: